Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.32 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27584843 | 0.86 | — | — | |
| SCHEMBL27664166 | 0.81 | LTA4H (0.30) | LTA4H | |
| SCHEMBL17468569 | 0.70 | HPGDS (0.37) | LTA4HHPGDSADRA1DADRA1AADRA1B | |
| SCHEMBL968047 | 0.70 | KCNH2 (0.33) | LTA4HKCNH2HRH3 | |
| SCHEMBL351341 | 0.69 | ADRA2A (0.39) | LTA4HKCNH2HRH3ADRA1A | |
| SCHEMBL100765 | 0.69 | HPGDS (0.46) | LTA4HHPGDSKCNH2ADRA1DADRA1A | |
| SCHEMBL15843275 | 0.68 | SMN1; SMN2 (0.35) | LTA4HKCNH2HRH3 | |
| SCHEMBL15843055 | 0.68 | SMN1; SMN2 (0.33) | LTA4HKCNH2HRH3 | |
| SCHEMBL31001159 | 0.67 | ADRA2A (0.37) | LTA4HKCNH2HRH3ADRA1A | |
| Methane SCHEMBL27599015 | 0.67 | ADRA2A (0.37) | LTA4HKCNH2HRH3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105198869-B | Oxazole oxazoline derivates, preparation method and its application in terms of plant pathogenic fungi antiseptic is prepared | 河南科技大学 | 2018-05-25 | — | — | CN | claimed |
| CN-105859713-B | A kind of harmel alkali oxazole oxazoline derivates and its preparation method and application | 华南农业大学 | 2017-08-08 | — | — | CN | claimed |
| CN-106350189-A | Special synthesized cutting fluid with ultra-high lubricating property for black metal and preparation method of special synthesized cutting fluid | 南京科润新材料技术有限公司 | 2017-01-25 | — | — | CN | claimed |
| EP-2326176-A1 | NON-AMIDIC LINKERS WITH BRANCHED TERMINI AS CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-06-01 | — | — | EP | claimed |
| CN-101998963-A | Insecticidal composition | DOW AGROSCIENCES LLC (US) | 2011-03-30 | — | — | CN | claimed |
| WO-2010021864-A1 | NON-AMIDIC LINKERS WITH BRANCHED TERMINI AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | claimed |
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-10421778-B2 | Isoform-selective lysine deacetylase inhibitors | WASHINGTON UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2019170055-A1 | COMPOUNDS HAVING CDK4/6 KINASE INHIBITORY ACTIVITY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-09-12 | — | — | WO | disclosed |
| US-10154997-B2 | Treatment of parasitic diseases using KDAC inhibitor compounds | WASHINGTON UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| CN-105198869-B | Oxazole oxazoline derivates, preparation method and its application in terms of plant pathogenic fungi antiseptic is prepared | 河南科技大学 | 2018-05-25 | — | — | CN | disclosed |
| CN-105198869-B | Oxazole oxazoline derivates, preparation method and its application in terms of plant pathogenic fungi antiseptic is prepared | 河南科技大学 | 2018-05-25 | — | — | CN | disclosed |
| CN-105198869-B | Oxazole oxazoline derivates, preparation method and its application in terms of plant pathogenic fungi antiseptic is prepared | 河南科技大学 | 2018-05-25 | — | — | CN | disclosed |
| CN-101341129-A | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-1703937-A | Organic electroluminescent device | IDEMITSU KOSAN CO (JP) | 2005-11-30 | — | — | CN | disclosed |
| CN-1635903-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2005-07-06 | — | — | CN | disclosed |
| CN-1444481-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1431904-A | Protease inhitors | SMITHKLINE BEECHAM CO (US) | 2003-07-23 | — | — | CN | disclosed |
| CN-1416346-A | Peotease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | CN | disclosed |
| CN-1251095-A | Lipase capalyzed dynamic resolution of isoxazoline thioester to isoxazoline carboxylic acids | PONT PHARMACEUTICAL CO DU (US) | 2000-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | LTA4H 987/4885HPGDS 107/4885KCNH2 4751/4885 |
| US-10421778-B2 | Isoform-selective lysine deacetylase inhibitors | DOT1L, KDM1A, HDAC1 | LTA4H 241/4885HPGDS 2228/4885KCNH2 1383/4885 |
| US-10154997-B2 | Treatment of parasitic diseases using KDAC inhibitor compounds | HSP90B1, TBCA, RPL17 | LTA4H 1888/4885HPGDS 718/4885KCNH2 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.